Posted by RedoxBox Europe SL
on November 29, 2023
Akkermansia muciniphila is a bacterium commonly found in the human gut microbiota and has been associated with potential metabolic health benefits. A proof-of-concept human study investigated the effects of A. muciniphila supplementation in overweight and obese individuals at increased risk of metabolic syndrome. The trial reported promising signals for safety and improvements in selected metabolic markers. In this article, we explore the rationale behind A. muciniphila supplementation and its potential as an emerging therapeutic approach for metabolic disorders.
The Role of Gut Microbiota in Metabolic Disorders
Metabolic syndrome refers to a cluster of risk factors that increase the likelihood of developing cardiovascular disease, stroke, and type 2 diabetes. It is typically characterized by central adiposity, elevated blood pressure, impaired glucose regulation, and dyslipidaemia. A growing body of research suggests that the gut microbiota plays a meaningful role in metabolic regulation by influencing energy harvest, inflammatory tone, gut barrier function, and host–microbe metabolic signalling. When the microbiota is disrupted (dysbiosis), these processes may shift toward insulin resistance and chronic low-grade inflammation, which are hallmarks of metabolic disease.
The Link Between Akkermansia muciniphila and Metabolic Disorders
Akkermansia muciniphila is a Gram-negative bacterium in the phylum Verrucomicrobia and is best known for residing in—and feeding on—the mucus layer lining the gut. Multiple observational studies have reported that A. muciniphila abundance is inversely associated with overweight/obesity and several metabolic risk states, including untreated type 2 diabetes and hypertension. Preclinical work in animal models has also suggested that increasing A. muciniphila (or using specific components derived from it) may improve metabolic outcomes, potentially through effects on gut barrier integrity and inflammation.
The Study
A clinical proof-of-concept study led by Dr. Patrice D. Cani (Université catholique de Louvain, Belgium) evaluated daily oral supplementation of A. muciniphila in overweight or obese, insulin-resistant adults. The trial was randomized, double-blind, and placebo-controlled. Primary endpoints focused on safety and tolerability, alongside metabolic outcomes such as insulin resistance, circulating lipids, visceral adiposity, and body mass. Secondary endpoints included gut barrier markers and gut microbiota composition. Participants received either live A. muciniphila or pasteurized A. muciniphila for three months, and supplementation was reported as safe and well tolerated.
The Results
Compared with placebo, pasteurized A. muciniphila was associated with improvements in several metabolic parameters. Reported changes included improved insulin sensitivity, reduced fasting insulinaemia, and a reduction in total cholesterol. Participants receiving pasteurized A. muciniphila also showed modest decreases from baseline in body weight, fat mass, and hip circumference. The intervention was additionally associated with reductions in certain blood markers linked to liver dysfunction and inflammation. Notably, the overall gut microbiome structure was reported to remain broadly unchanged, suggesting the observed effects may not require large-scale microbiome restructuring.
Conclusion
This proof-of-concept clinical trial (NCT02637115) suggests that A. muciniphila supplementation—particularly in pasteurized form—can be safe and may improve specific metabolic markers in insulin-resistant adults with overweight/obesity. While these findings are encouraging, they are preliminary and should be interpreted in the context of an exploratory, early-stage human study. Larger trials are needed to confirm efficacy, clarify mechanisms, and determine which populations may benefit most.
REFERENCES & FURTHER READING